Baidu
map

Arch Orthop Trauma Surg:富含血小板的血浆在早期VS.晚期膝关节骨性关节炎中的应用

2023-04-28 MedSci原创 MedSci原创 发表于上海

骨关节炎(OA)是导致中老年人疼痛和残疾的一个主要原因。虽然多种治疗方法被推荐用于缓解症状和延长生活质量,但没有足够的证据表明一种治疗方法是否优于另一种。

膝关节骨性关节炎(OA)是导致中老年人疼痛和残疾的一个主要原因。虽然多种治疗方法被推荐用于缓解症状和延长生活质量,但没有足够的证据表明一种治疗方法是否优于另一种。有报告认为,富含血小板的血浆(PRP)是治疗OA的一种有效和安全的生物方法。然而,PRP在疾病的晚期阶段的有效性并不完全清楚。近日,发表于Arch Orthop Trauma Surg的一项综述旨在评估在对早中期膝关节OA患者的研究中,与包括根据Kellgren-Lawrence分类的晚期OA患者的研究相比,使用PRP是否会同样有效。

研究人员系统检索了MEDLINE、EMBASE、Scopus和Web of Science数据库中,以确定随机对照试验(RCTs),比较PRP注射与其他关节内治疗对疼痛和功能的影响。使用随机效应模型和通用反方差法进行了荟萃分析。

 

结果,研究人员共纳入了31项临床试验,报告了2705名受试者的数据。荟萃分析显示,疼痛[MD, - 1.05 (95% CI - 1.41 至 - 0.68); I2 = 86%; P ≤ 0.00001]和功能[SMD, - 1.00 (95% CI - 1.33, 至 - 0.66); I2 = 94%; P ≤ 0.00001]都有明显改善,有利于PRP。疼痛和功能改善的子分析显示,在Kellgren-Lawrence OA 1-3和1-4期的研究中,疼痛明显缓解,在膝关节OA 1-2、1-3和1-4期的研究中,功能明显改善,有利于PRP。

综上所述,该研究结果表明,在包括早期-中度膝关节OA的研究中,以及包括疾病晚期的研究中,疼痛和功能都有明显的改善。包括晚期膝关节OA患者并不影响评估PRP对膝关节OA有效性的临床试验的结果。研究的局限性在于所纳入的研究中临床和方法学研究间的异质性很高,可能与以下几个因素有关: 1)PRP疗法与各种注射疗法进行比较,2)PRP配方的多样性,3)随访的差异,以及4)不同的治疗方案(注射次数和间隔时间)。

 

原始出处:

 

Félix Vilchez-Cavazos, et al., The use of platelet-rich plasma in studies with early knee osteoarthritis versus advanced stages of the disease: a systematic review and meta-analysis of 31 randomized clinical trials. Arch Orthop Trauma Surg. 2023 Mar;143(3):1393-1408. doi: 10.1007/s00402-021-04304-1.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2129555, encodeId=d6f82129555ce, content=不错,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=270c2278999, createdName=121bfa5am47暂无昵称, createdTime=Mon May 01 14:06:16 CST 2023, time=2023-05-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2128986, encodeId=0022212898646, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Fri Apr 28 13:24:00 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2128984, encodeId=2f9121289844e, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Apr 28 12:57:05 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2128978, encodeId=1a9221289e895, content=不错,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Fri Apr 28 11:55:31 CST 2023, time=2023-04-28, status=1, ipAttribution=吉林省)]
    2023-05-01 121bfa5am47暂无昵称 来自广东省

    不错,学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2129555, encodeId=d6f82129555ce, content=不错,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=270c2278999, createdName=121bfa5am47暂无昵称, createdTime=Mon May 01 14:06:16 CST 2023, time=2023-05-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2128986, encodeId=0022212898646, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Fri Apr 28 13:24:00 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2128984, encodeId=2f9121289844e, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Apr 28 12:57:05 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2128978, encodeId=1a9221289e895, content=不错,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Fri Apr 28 11:55:31 CST 2023, time=2023-04-28, status=1, ipAttribution=吉林省)]
    2023-04-28 yangchou 来自浙江省

    好文章,谢谢分享。

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2129555, encodeId=d6f82129555ce, content=不错,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=270c2278999, createdName=121bfa5am47暂无昵称, createdTime=Mon May 01 14:06:16 CST 2023, time=2023-05-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2128986, encodeId=0022212898646, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Fri Apr 28 13:24:00 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2128984, encodeId=2f9121289844e, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Apr 28 12:57:05 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2128978, encodeId=1a9221289e895, content=不错,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Fri Apr 28 11:55:31 CST 2023, time=2023-04-28, status=1, ipAttribution=吉林省)]
    2023-04-28 1209e435m98(暂无昵称) 来自浙江省

    学习了,谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2129555, encodeId=d6f82129555ce, content=不错,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=270c2278999, createdName=121bfa5am47暂无昵称, createdTime=Mon May 01 14:06:16 CST 2023, time=2023-05-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2128986, encodeId=0022212898646, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Fri Apr 28 13:24:00 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2128984, encodeId=2f9121289844e, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Apr 28 12:57:05 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2128978, encodeId=1a9221289e895, content=不错,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Fri Apr 28 11:55:31 CST 2023, time=2023-04-28, status=1, ipAttribution=吉林省)]
    2023-04-28 仁术2021 来自吉林省

    不错,学习了。

    0

相关资讯

Ann Rheum Dis:特应性疾病患者骨关节炎风险增加

骨关节炎(OA)是最常见的关节炎形式,终生罹患症状性膝关节炎的风险高达44.7%。本研究的目的是调查特应性疾病患者患骨性关节炎的风险是否增加。

A&R:过量的生长激素加重小鼠关节退行性变和软骨细胞代谢功能障碍

描述过表达牛生长激素(bGH)或生长激素受体拮抗剂(GHa)的小鼠的关节病理,还研究了生长激素对软骨细胞代谢的调节作用。

Sci Rep:蒲地兰片对碘乙酸钠所致小鼠骨关节炎的保护作用

骨关节炎(OA)是目前最常见的慢性退行性关节疾病。蒲地兰片(PDL)是一种著名的中药配方,用于临床治疗慢性炎症性疾病。该研究探索了PDL在体外和体内的抗炎和抗OA特性,以及PDL治疗OA的机制。

JAMA子刊:“神药”可显著降低2型糖尿病患者骨关节炎发生风险!

JAMA Netw Open:二甲双胍与磺酰脲类治疗的成人 2 型糖尿病患者骨关节炎的发展

Physiotherapy:踝关节骨性关节炎临床研究中的结果措施 :系统回顾

骨关节炎(OA)是常见的致残病因。踝关节OA患者的生活质量、身体残疾和心理健康都会受到影响,这与髋关节OA末期、肾衰竭和充血性心力衰竭患者的情况类似。

Am J Sports Med:富血小板血浆在治疗膝关节骨性关节炎方面与其他疗法的临床比较如何?

人们对生物疗法在膝关节骨关节炎等骨科疾病中的应用越来越感兴趣。富含血小板的血浆(PRP)是这些疗法之一,但它仍然缺乏一致的结果。

Baidu
map
Baidu
map
Baidu
map